A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance

Jia Liu,Lei Zhao,Lin Shi,Ye Yuan,Daan Fu,Zhilan Ye,Qilin Li,Yan Deng,Xingxin Liu,Qiying Lv,Yanni Cheng,Yunruo Xu,Xulin Jiang,Guobin Wang,Lin Wang,Zheng Wang
DOI: https://doi.org/10.1021/acsami.0c13852
2020-09-22
Abstract:Cancer chemotherapy is challenged by multidrug resistance (MDR) mainly attributed to overexpressed transmembrane efflux pump P-glycoprotein (P-gp) in cancer cells. Improving drug delivery efficacy while co-delivering P-gp inhibitors to suppress drug efflux is an often-used nanostrategy for combating MDR, which is however challenged by cascaded bio-barriers en route to cancer cells and P-gp inhibitors' adverse effects. To effectively breach the cascaded bio-barriers while avoiding P-gp inhibitors' adverse effects, a stealthy, sequentially responsive doxorubicin (DOX) delivery nanosystem (RCMSNs) is fabricated, composed of an extracellular-tumor-acidity-responsive polymer shell (PEG-<i>b</i>-PLLDA), pH/redox dual-responsive mesoporous silica nanoparticle-based carriers (MSNs-SS-Py), and cationic β-cyclodextrin-PEI (CD-PEI) gatekeepers. The PEG-<i>b</i>-PLLDA corona makes RCMSNs stealthy with prolonged blood circulation time. Once tumors are reached, extracellular acidity degrades PEG-<i>b</i>-PLLDA, reversing nanosystem's surface charges to be positive, which drastically improves RCMSNs' tumor accumulation, penetration, and cellular internalization. Within cancer cells, CD-PEI gatekeepers detach to allow DOX unloading in response to intracellular acidity and glutathione and functionally act as a P-gp inhibitor, dampening P-gp's efflux activity by impairing ATP production. Thus, the resultant high-efficacy drug delivery along with reduced P-gp function cooperatively reverses MDR <i>in vitro</i>. Importantly, in preclinical tumor models, potently suppress MDR tumor growth without eliciting systemic toxicity, demonstrating their potential of clinical translation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c13852?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c13852</a>.Methods, NMR spectra, characterizations of UCMSNs, flow cytometry analysis, and pharmacokinetics parameters (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c13852/suppl_file/am0c13852_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
materials science, multidisciplinary,nanoscience & nanotechnology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the multi - drug resistance (MDR) in cancer chemotherapy, especially the drug efflux phenomenon caused by the over - expressed transmembrane efflux pump P - glycoprotein (P - gp). Specifically, the paper proposes a sequentially responsive nanosystem (RCMSNs), aiming to overcome a series of biological barriers and inhibit the function of P - gp, thereby reversing the drug resistance of cancer cells to chemotherapy drugs. ### Problems Solved by the Paper: 1. **Multi - drug Resistance (MDR)**: - One of the major challenges in cancer chemotherapy is multi - drug resistance. In particular, P - glycoprotein (P - gp) over - expressed in cancer cells actively pumps drugs out of the cells, resulting in a decrease in intracellular drug concentration and thus affecting the treatment effect. - Formula representation: \[ \text{MDR} = f(\text{P - gp expression}) \] 2. **Low Drug Delivery Efficiency**: - Traditional chemotherapy drugs face multiple physiological barriers (such as blood circulation, tumor accumulation, tumor penetration, cell internalization, and drug release) during the delivery process, making it difficult for drugs to effectively reach the target site. - Formula representation: \[ \text{Drug delivery efficiency} = f(\text{bio - barriers}) \] 3. **Side Effects of P - gp Inhibitors**: - The use of additional P - gp inhibitors may cause adverse systemic toxicity, which makes the manufacturing of the nanosystem more complicated. - Formula representation: \[ \text{Toxicity} = f(\text{P - gp inhibitors}) \] ### Solutions: In order to effectively break through these biological barriers and avoid the side effects of P - gp inhibitors, the research team designed a sequentially responsive doxorubicin (DOX) - delivery nanosystem (RCMSNs). This system consists of three functional components: 1. **Tumor - acid - responsive polymer shell (PEG - b - PLLDA)**: - It remains stealth in the blood circulation, prolonging the blood circulation time; after reaching the tumor, it degrades in response to the acidic environment, reversing the surface charge of the nanosystem to positive, thereby significantly improving tumor accumulation, penetration, and cell internalization. 2. **pH/redox dual - responsive mesoporous silica nanoparticle carrier (MSNs - SS - Py)**: - It rapidly releases the loaded drugs in response to acidic and glutathione (GSH) conditions inside the cell. 3. **Cationic β - cyclodextrin - PEI (CD - PEI) blocker**: - It not only acts as a gatekeeper to control drug release but also inhibits the function of P - gp by interfering with ATP production. ### Experimental Results: - **In vitro experiments**: This nanosystem can efficiently deliver drugs and inhibit the efflux function of P - gp, significantly improving the anti - cancer effect. - **In vivo experiments**: In pre - clinical tumor models, DOX@RCMSNs effectively inhibits the growth of drug - resistant tumors without causing systemic toxicity, showing potential clinical translation value. In conclusion, this paper proposes an innovative nanodelivery system that can effectively overcome the multi - drug resistance problem and provides new ideas and methods for cancer chemotherapy.